Alejandro Durán-Méndez

Alejandro Durán-Méndez

Auto-generated profile, based on publicly available information

Alejandro Durán-Méndez

Universidad Autónoma del Estado de Hidalgo

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ADAlejandro Durán-Méndez
Alejandro Durán-Méndez
AAAlma Delia Aguilar-Arroyo
Alma Delia Aguilar-Arroyo
EVEmiliano Vivanco-Gómez
Emiliano Vivanco-Gómez
ENEduardo Nieto-Ortega
Eduardo Nieto-Ortega
DPDaniela Pérez-Ortega
Daniela Pérez-Ortega
APAlberto N. Peón
Alberto N. Peón
Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to variations in the dose of tocilizumab used, the stage in which the drug is administered or the severity of disease presentation. Thus, we performed a retrospective multicentric study in 140 patients with moderate to critical COVID-19, 79 of which received tocilizumab in variable standard doses (< 400 mg, 400–800 mg or > 800 mg), either at the viral (1–7 days post-symptom onset), early inflammatory (8–15) or late inflammatory (16 or more) stages, and compared it with standard treated patients. Mortality, reduced respiratory support requirements and pathology markers were measured. Tocilizumab significantly reduced the respiratory support requirements (OR 2.71, CI 1.37–4.85 at 95%) and inflammatory markers (OR 4.82, CI 1.4–15.8) of all patients, but mortality was only reduced (4.1% vs 25.7%, p = 0.03) when the drug was administered at the early inflammatory stage and in doses ranging 400–800 mg in severely-ill patients. Despite the apparent inability of Tocilizumab to prevent the progression of COVID-19 into a critical presentation, severely-ill patients may be benefited by its use in the early inflammatory stage and moderate doses.

10 June 2021
Verified
Journal Article
Closed access
ADAlejandro Durán-Méndez
Alejandro Durán-Méndez
MTMiranda Tobón-Cubillos
Miranda Tobón-Cubillos
AVAmérica Viveros-Hernández
América Viveros-Hernández
JHJorge Rafael Flores Hernández
Jorge Rafael Flores Hernández
JMJuan Daniel Méndez-Coca
Juan Daniel Méndez-Coca
APAlberto N. Peón
Alberto N. Peón
In the last 40 years new vaccine technologies have arisen, promising easy and quick formulation and design. In the scenario of a rapidly-spreading infectious pathogen, these technologies may render an adequate strategy to counter the pandemic. As such, me review the engineering and mechanisms of action of the main anti-COVID-19 vaccines.

5 January 2022 in Pädi Boletín Científico de Ciencias Básicas e Ingenierías del ICBI
Verified
Journal Article
Open access
PDF file
ADAlejandro Durán-Méndez
Alejandro Durán-Méndez
ENEduardo Nieto-Ortega
Eduardo Nieto-Ortega
APAlberto N. Peón
Alberto N. Peón
La COVID-19 tiene un espectro clínico variable, desde una infección asintomática hasta una enfermedad crítica con desenlace mortal. Se han propuesto múltiples terapias, algunas con efectos a nivel de la respuesta inmunológica. En este estudio evaluamos el uso de Tocilizumab, Colchicina y Baricitinib en pacientes hospitalizados con infección por SARS-CoV-2. Se examinaron los expedientes clínicos de 133 pacientes hospitalizados con COVID-19 en 3 hospitales. Inicialmente, ninguno de estos medicamentos mostró ser superior al grupo Control en disminuir la mortalidad. Sin embargo, se realizó un análisis estratificado evidenciando que Tocilizumab puede reducir la mortalidad hasta un 3.7% vs 28.12% (p=0.01). La estancia intrahospitalaria fue mayor en los pacientes que recibieron Baricitinib y Tocilizumab comparados con el Control (14.25±2.06 y 10.58±3.66 respectivamente vs 8.30±2.86). Finalmente, Tocilizumab fue el único fármaco que redujo la probabilidad de un aumento en el requerimiento de oxígeno suplementario (OR 0.3094, 0.95% IC [0.1031-0.9287]). La terapia inmunorreguladora muestra ser útil para el manejo de pacientes con COVID-19.